MondayNightIBD Livestream Pretest: Raising the Bar in the Care of Patients with Crohn’s Disease: Evidence-Based Strategies for Improved Outcomes (ID: i800-3)

Question Title

* 1. How confident are you in the management of patients with Crohn's disease (CD) in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 2. In the CALM trial, significantly more patients achieved deep remission at week 48 in the treat to target arm than in the clinical management arm. Deep remission is defined as which of the following?

A combination of reduced CRP and fecal calprotectin levels and mucosal healing

Crohn’s disease endoscopy index of severity of 0

A combination of steroid-free clinical remission and mucosal healing with no deep ulcers

Question Title

* 3. Callie is a 60-year-old woman with severely active CD. Her medical history includes HTN, psoriasis, and treatment for breast cancer 3 years ago. Based on current AGA recommendations for the positioning of therapies for Crohn’s disease, which of the following would you select as first-line treatment for this patient?

AZA/MP

ADAL/CZP/IFX

UST

VDZ

Question Title

* 4. In the recent SEAVUE head-to-head comparison study, which of the following safety outcomes showed the widest numerical difference between UST-treated vs ADA-treated patients with Crohn’s disease, in favor of UST?

Serious infections

Death

Malignancy

AEs leading to discontinuation

Question Title

* 5. Which of the following baseline patient characteristics is associated with the highest risk of developing antibodies to anti-TNF therapy?

0 copies of DQA1*05, immunomodulators

0 copies of DQA1*05, no immunomodulators

≥1 copy of DQA1*05, immunomodulators

≥1 copy of DQA1*05, no immunomodulators